3/4
05:37 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
3/3
11:03 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
3/3
11:03 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
3/3
08:10 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
2/11
06:16 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
2/10
08:00 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
1/13
11:15 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
1/13
11:15 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
1/13
11:09 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
1/13
08:09 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $15.00 price target on the stock, down previously from $40.00.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $15.00 price target on the stock, down previously from $40.00.
1/13
08:04 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
1/10
05:45 pm
fdmt
4D Molecular downgraded to Market Perform from Outperform at BMO Capital
High
Report
4D Molecular downgraded to Market Perform from Outperform at BMO Capital
1/10
05:45 pm
fdmt
4D Molecular downgraded to Market Perform from Outperform at BMO Capital
High
Report
4D Molecular downgraded to Market Perform from Outperform at BMO Capital